✦ LIBER ✦

Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer

✍ Scribed by Patrick W. Sullivan; Joel B. Nelson; Parvez M. Mulani; Darryl Sleep

Publisher: Springer Netherlands
Year: 2006
Tongue: English
Weight: 183 KB
Volume: 15
Category: Article
ISSN: 0962-9343
DOI: 10.1007/s11136-006-0003-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality of life findings from a multicen

Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer

✍ Patrick W. Sullivan; Parvez M. Mulani; Mayer Fishman; Darryl Sleep 📂 Article 📅 2007 🏛 Springer Netherlands 🌐 English ⚖ 148 KB

A phase I study of the somatostatin anal

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer

✍ William D. Figg; Alain Thibault; Michael R. Cooper; Robert Reid; Donna Headlee; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

Quality of life impact of three differen

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma : Results of Intergroup 0159/Cancer and Leukemia Group B 9480

✍ Tim A. Ahles; James E. Herndon II; Eric J. Small; Nicholas J. Vogelzang; Alice B 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

Is there a role for platinum chemotherap

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

✍ William K. Oh; Miah-Hiang Tay; Jiaoti Huang 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 3 views

POSSUM and Its Related Models as Predict

POSSUM and Its Related Models as Predictors of Postoperative Mortality and Morbidity in Patients Undergoing Surgery for Gastro-oesophageal Cancer: A Systematic Review

✍ Sumanta Dutta; Paul G. Horgan; Donald C. McMillan 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 195 KB

A phase 3 randomized controlled trial of

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro